SCHEMBL10134085

SCHEMBL10134085

COC(=O)c1ccc(Nc2ccc(Cl)n3ccnc23)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.39
PTK2 Q05397 4/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
TGFBR1 P36897 1/20 0.36
P2RX3 P56373 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
CNR2 P34972 1/20 0.35
MAPT P10636 2/20 0.34
ALOX15 P16050 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
MAPKAPK5 Q8IW41 1/20 0.34
USP2 O75604 1/20 0.34
PABPC1 P11940 1/20 0.34
BCL6 P41182 1/20 0.33
BCOR Q6W2J9 1/20 0.33
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134099 0.88 CYP1A2 (0.39) AURKAAURKBCNR2MAPTMEN1
SCHEMBL1685103 0.82 SIRT2 (0.45) AURKAMAPTMEN1KMT2ABCL6
SCHEMBL13281267 0.79 KDM4E (0.41) PTK2MAPTLMNAPOLB
SCHEMBL22101263 0.78 RAB9A (0.47) TRPV1CNR2MAPTALOX15MEN1
SCHEMBL1685147 0.73 AURKA (0.44) AURKAAURKBMAPTMEN1KMT2A
SCHEMBL22101200 0.70 ATR (0.44) AURKAAURKBTGFBR1P2RX3TRPV1
SCHEMBL16645313 0.69 HDAC1 (0.57) MAPTALOX15MEN1KMT2A
SCHEMBL13392078 0.68 SMN1; SMN2 (0.45) MAPTMEN1KMT2ALMNA
SCHEMBL16608985 0.67 MAPT (0.55) MAPTALOX15MEN1KMT2ALMNA
SCHEMBL4833247 0.66 SMN1; SMN2 (0.46) MAPTALOX15MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 SYK 1605/4885PTK2 71/4885AURKA 3833/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 SYK 1605/4885PTK2 71/4885AURKA 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.